Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunome Inc
(NQ:
IMNM
)
25.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
25.52
Bid (Size)
25.41 (8)
Ask (Size)
26.65 (1)
Prev. Close
25.52
Today's Range
25.52 - 25.52
52wk Range
4.440 - 30.96
Shares Outstanding
42,729,847
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Performance
YTD
+131.79%
+131.79%
1 Month
+2.82%
+2.82%
3 Month
+145.86%
+145.86%
6 Month
+238.01%
+238.01%
1 Year
+420.82%
+420.82%
More News
Read More
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
March 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Immunome to Participate in the Leerink Partners Global Biopharma Conference
March 07, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
March 01, 2024
From
Immunome, Inc.
Via
Business Wire
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
February 28, 2024
Via
Benzinga
How I Swing Trade Via Strength With Recent Examples
February 25, 2024
Via
Talk Markets
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 16, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Proposed Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 06, 2024
Via
Benzinga
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome - Oncology Is Hot
January 10, 2024
Via
Talk Markets
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
January 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Roberts as Chief Technical Officer
January 04, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Carol A. Schafer to Board of Directors
January 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
December 26, 2023
From
Immunome, Inc.
Via
Business Wire
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
December 26, 2023
From
Atreca, Inc.
Via
GlobeNewswire
Immunome to Present at the Stifel 2023 Healthcare Conference
November 10, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Immunome, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.